Lucid Diagnostics Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
LUCD$0.40-4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
for the YEARS ENDED December 31, 2024 and 2023
| Preferred Stock · Common Stock · Additional Paid-In · Accumulated | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | Total | |
| Balance as of December 31, 2022 | — | $— | 40,518,792 | $41 | $121,081 | $(98,075) | $23,047 |
| Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan | — | — | — | — | 5,762 | — | 5,762 |
| Stock-based compensation - PAVmed Inc. 2014 Equity Plan | — | — | — | — | 1,060 | — | 1,060 |
| Vest - restricted stock awards | — | — | 303,980 | — | — | — | — |
| Conversions - Senior Secured Convertible Note | — | — | 115,388 | — | 166 | — | 166 |
| Issuance common stock - APA-RDx - Termination payment | — | — | 553,436 | — | 713 | — | 713 |
| Issuance - At-The-Market Facility, net of financing charges | — | — | 230,068 | 1 | 283 | — | 284 |
| Purchase - Employee Stock Purchase Plan | — | — | 508,200 | — | 551 | — | 551 |
| Issuance - Series A and Series A-1 Preferred Stock | 18,625 | 18,625 | — | — | — | — | 18,625 |
| Issue common stock - vendor service agreement | — | — | 100,000 | — | 147 | — | 147 |
| Net loss | — | — | — | — | — | (52,666) | (52,666) |
| Balance as of December 31, 2023 | 18,625 | $18,625 | 42,329,864 | $42 | $129,763 | $(150,741) | $(2,311) |
| Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan | — | — | 3,333 | — | 4 | — | 4 |
| Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan | — | — | — | — | 4,183 | — | 4,183 |
| Stock-based compensation - PAVmed Inc. 2014 Equity Plan | — | — | — | — | 351 | — | 351 |
| Vest - restricted stock awards | — | — | 26,912 | — | — | — | — |
| Conversions - Senior Secured Convertible Note | — | — | 13,866,867 | 14 | 13,468 | — | 13,482 |
| Purchase - Employee Stock Purchase Plan | — | — | 647,940 | 1 | 446 | — | 447 |
| Issuance - Series A-1 Preferred Stock | 5,670 | 5,670 | — | — | — | — | 5,670 |
| Exchange - Series A and Series A-1 Preferred Stock | (24,295) | (24,295) | — | — | — | (7,496) | (31,791) |
| Issuance through exchange - Series B and Series B-1 Preferred Stock | 31,790 | 31,790 | — | — | — | — | 31,790 |
| Issuance through sale- Series B and Series B-1 Preferred Stock | 24,129 | 24,129 | — | — | — | — | 24,129 |
| Conversions - Series B Preferred Stock | (1,500) | (1,500) | 2,075,263 | 2 | 1,498 | — | — |
| Issuance - Due To: PAVmed Inc. Settlement in Common Stock | — | — | 3,331,771 | 3 | 4,672 | — | 4,675 |
| Issue common stock - vendor service agreement | — | — | 790,000 | 1 | 640 | — | 641 |
| Transfer of intellectual property from PAVmed Inc. | — | — | — | — | (350) | — | (350) |
| Net loss | — | — | — | — | — | (45,529) | (45,529) |
| Balance as of December 31, 2024 | 54,419 | $54,419 | 63,071,950 | $63 | $154,675 | $(203,766) | $5,391 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.